Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GEN News Highlights More »
May 22, 2007
Pluristem Buys Patents Covering Stem Cell Production Tool for $2M
This was allo's big find today, and it has surely paid handsomely since 2007.
Great find.
Time to change up management, they are NOT deal makers, obviously....imhop
X2 Blue!
Flush twice, rinse and repeat.
Mr. Aberman was awarded the Rothschild Prize!
Thanks allo. I think this should actually get posted on the WGAS Channel.
This and $.50 will get you a cup of coffee.
What have you done for me lately? Thanks for posting this allo, it is SURE to spike the price today.
Yawn.
Looks like the Controller brought the price
back up at the end of day! ;>)
Did somebody say...
Looks like the Controller brought the price
back up at the end of day! ;>)
Did somebody say...
Did somebody say...
Breaking PSTI NEWS!
Yaky's youtube video is up to 76 views, including allo and her 74 alias'
Yeah, the world can hardly wait; it mus have 'The Controller' scared to death. Yawn.
Columbine Capital Services, Inc. downgrades PSTI from FAVORABLE to NEUTRAL.
Wow, allo finds the investors that bought shares in 2004, but misses this. Would expect more from our level-headed & credible analyst.
Must have watched Yaky's video.
that was a real eye opener for me.....
Blue, yes, you see it. So is everyone else now too. allo cannot put enough polish on these turds.
Yaky was as nervous as a, well, you know, in church. To call him an Amateur is an insult to Amateurs everyewhere. I'm sure he is drawing from his'experience'to come up with these crafty and pusuasive tweedle dee and tweedle dumb presentations.
To think of the nerve-racking nature of a JP speaker panel - oh my. If you watched the video, you can't even blame it on the language barrier and pass the red face test.
Yaky, pop a couple xanax, a beta-blocker and just go with it.
Cheers!
PS - always practice in front of a mirror, and remember the little red engine!
New cracks found in
Allo's head.
Sometimes, their own words make the (incompetence) points better than us...
Yaky simply cannot even answer a softball question, about is "Day Job".
"What is Pluristem doing...healthcare costs etc." Babble, tangent, Huh?!
Then, the 'in my pocket' quote.
You can now see with your own eyes. CAN YOU IMAGINE this guy trying to negotiate when he cannot even clearly and succintly articulate simple responses on a newspaper panel?
Watch and then ask yourself why it is so uncomfortable & painful to watch. What do you think Eric Schmidt or other 'real' bio analysts (PhD,MD,etal.) think when they hear him talk? - THAT (Leadership) is the issue, remember the products are awesome.
auto, I was wrong about you, 100% accurate with....
blue- appreciate that; however, I do not like being right about this one...it is sad, actually.
Welcome back, Spideboy! Missed you. Still awaiting your scientific, fact-filled response below.
PS, be VERY careful, It looks like you may be getting dragged (taken hostage) into FDAapproved, Allo, Buteo, FDAwillapprove, et.al.'s formal SEC complaint on Tuesday, "Failure to disclose affiliation"... while making claims as to PLX Cells & IPS, directly to a 'patient' on another board. Said the spider to the fly...
Auto1 Thursday, 05/25/17 01:18:45 AM
Re: Spideyboy post# 5156
Post #
5220 of 5360 Go
Spidey, sorry for slow response, been elsewhere making money... This is a long one, but important, educational & entertaining. Grab a cold one and some popcorn and follow along.
Spideyboy (Thomas),
I've just read your continuing posts over the last couple of days and I appreciate the humor. I'm not sure which you have the least of... scientific or business accumen, it's too close to call. You have clarified your lack of training, working knowlege of clinical trials, design, data, science, statistics & analysis of the like. I'll describe below, using your own post.
Btw, it only took me 3 clicks, to find Thomas. (I have really smart computers), not "going though my approx 50 previous posts" - don't flatter yourself - to learn a lot, including the fact you have 0 medical/science training or background.
Anywhoo. Here we go.
1) In your post below, "Another new bit of exciting data and in foloow-up analysis" - You stated "This is fantastic in comparison with Neupogen" - this is your 1st display of gross incompetence regarding clinical trials and scientific rigor. You cannot (scientifically) compare clinical trials, unless they are head-to-head. Next, you are going BACK to MICE data to claim 'superiority' of R18, and I quote in your 'science silver tongue' "very significantly better" "similiar or stronger support" (giggle) over a product that has been proven, approved & indicated for ARS, actually used in Humans. Your science-speak wouldn't pass on an exhibit at the science fair, much less among the educated. Put the shovel down wrt Neupogen. It's approved and indicated, and It Works.
2) You stated "particularly when it comes to the Japanese, things are almost invariably delayed. Japanese working culture is still quite traditional and requires unanimity of agreement on virtually everything and this can draw things out significantly." - oh my, did you really just say that? "unanimity" "everything" - what a stereotype, do you have something against the Japanese? DO TELL of your experiences in Japan, negotiating with pharma. You Sir, are insulting. You may have not heard of Toyota, Honda, Nissan, Takeda, etc. - they seemed to move at sufficient speed over the last 50 years, surgically dismantling the US automotive industry. Do some study on Edwards Deming. Remember him from your MBA classes - oh that's right, you don't have one of those either.
3) RE The Chinese, you state "it is very important to properly access the China market" now that the obvious has been covered, "China doesn't like companies coming by themselves and making significant steps there." Really? State your example(s)/source. Huh? After you tell us of your business dealings in Japan, please share yhour direct dealings in China too. I have that as well. "due to the China policy" - what 'policy' - name it!?! bs... "with many superior attributes to Neupogen" - there you go again. "and now looks to sign with the US government for a further cash injection." Thomas, your latest post #5176 outlining the Chinese drug reimburesement process, with such command of where PLX would find its place, was simply, in-a-word, Amazing. Has this been your personal experience at the table, in China? Yikes! http://www.fiercebiotech.com/special-report/top-10-big-pharma-investments-china - innovation drives demand and price - at least that has been my experience internationally including Asia & the Far East.
4) #2 example of clinical/scientific incompetence - "# of primates for pivitol study with R18." Really well thought out again, spidey - just look at the Neupogen Study designs and guess. Wow, good stuff. "I would suspect to the higher range" Pssst, its a little more complex than that, involves endpoints, probabilities, statistics and moa of the drug being evaluated, to name a few. (giggle again)
5) RE Timing of US 'stockpiling' "Well lets not get ahead of ourselves" as you say. Maybe we should get them to agree to pay for the pivitol study first, workout our pricing strategy (so we don't bastardize all of the other indications), and have some (any) HUMAN safety data signals from the interim analyis of the R18 Open Label, HCT Insufficient Responders trial, first, shall we?
6) You stated "I initially did the comparison due to Auto1's comments in his post #5073, where Auto1 stipulated 'Neupogen data was better than R18'. This had me concerned so did the DD and thought it would be good to share." spidey, this one is SO RICH, get ready. Here is my actual post, un-edited, Thomas. May I call you Thomas? If you are going to quote me and then 'pontificate', at least get the full quote correct, please. I stated, "Neupogen data (unscientifically) was BETTER than R18. Look for your self at the improvement vs. controls" - Now, you know why it is unscientific, I stated that above, even though your analysis is steeped in unscientific deductions and extrapolations. Now, since you went there, I'm going to show that your math skills are in question also. UNSCIENTIFICALLY, but following your analysis and logic: ARS Primate Survival - Neupogen 79%/41% control = 38% survival advantage.
PLX 85%/50% control = 35% survival advantage. 38% > 35% Neupogen wins. Unfortunately, in the real world, you cannot do this. Nevertheless, Ecellent DD on your part, Thomas. PS - #3 example of clinical/scientific incompetence
7) WRT #5113 and poor research, let me clarify, the trials you cite are not poor research. Your research is poor research, Spidey. You see you used 2 trials that were 'dose & duration' finding studies that were used to 'inform' the final primate pivitol trial for N - where you showed N had a 0% survival outcome. NO KIDDING - that is where it was determined the N dose should be delivered within 24 hours of exposure! - When this is done, as found in the Pivitol primate trial, the study actually gets stopped EARLY because of 'profound' efficacy and survival. This is #4 example of your clinical/scientific incompetence. For some reason, you like to look back at the wrong studies, that really don't matter anymore. Just like you did above with the mice. At least you are consistent however; consistently wrong.
8) "And thanks to Auto1's post today #5141 that I quote below:
"“We intend to develop this technology platform into a functional stem cell production system for the treatment of a variety of indications; the first being a safe, effective, and efficient ALTERNATIVE to bone marrow transplantation,” according to Pluristem chairman and CEO, Zami Aberman - May 22, 2007""
And probably your best example, spidey, of your clinical/scientific trial incompetence (#5), although the others were close, my "no idea" question - "When will this "first" trial commence?" you replied "This shows Auto1 has no idea what he/she's talking about or investing in" - REALLY? NO IDEA?, do you REALLY want to go with that? Ok, have it your way... Thomas, do you know the definition of the word "ALTERNATIVE" (available as another possibility, or in place of)- It would appear NOT.
You see, Thomas, here is the title of the trial you cite as the ANSWER to my "no idea" question. "Phase 1 Clinical Trial of R18 for the treatment of insufficient hematopoietic recovery FOLLOWING hematopoietic cell transplantation" - Thomas, this trial is called a "non-responder or inadequate or insufficient responder trial" - IF you look closely (or read, as you criticize me) it's in the title of the trial. You see, HCT (hematopoietic cell transplantation) is the first-line treatment in this study. Then, R18 is used, AFTER HCT, NOT AS AN "ALTERNATIVE". So my question above, is quite germain, and as of yet, UNANSWERED, even though this is what Zami promissed us back in 2007, to be "THE FIRST" trial. This trial has not even been proposed, much less conducted or even underway.
So, I don't think I am the one who has "no idea" what they are talking about, spideyboy...
In closing, in you words #5179, "I only write to clarify situations and provide any analysis, insight, based on sources and experience that I might know of that may impact product/company success."
spidey, thanks for the clarification, analysis & insight outlined above from your sources and experience!
- Best advice I can give... Don't lead with your chin.
- Auto1
industry is moving ahead faster than what we think or know, not about PSTI having a lack of leadership....
Well played, Blue.
To NOT invest in a Chief Commerical Officer with unparalled experience at this stage (T -12 to 24 mos.) only sends a message of a lack of confidence in the products OR the actual distance between now and a potential approval is far longer than being communicated. - IMHO
Think about it, they cannot have it both ways - we are either near-term and therefore the 'billions' expected from this miracle make hiring/paying 'the best' deal maker a teardrop in the ocean in comparison. Or... we are not.
Either way, Investors will stay away until there is some kind of signal other than a powerpoint presentation on a web page.
Competition is heating up, come on Pluristem, we need a deal soon......imhop
X2 - Going, Going...
Leadership matters...great post, bluehorsesho
This is what a biotech/regen leadership team looks like folks...and backed by a STRONG Board Of Directors.
"Mr. Cartt and Mr. Mulroy worked closely together for many years at Questcor Pharmaceuticals, a company they built together along with Asterias Chairman Don Bailey and CFO Ryan Chavez, before its eventual sale in 2014 to Mallinckrodt plc for $5.6 billion."
That's BILLION, with a B.
https://finance.yahoo.com/news/asterias-biotherapeutics-announces-top-leadership-201000363.html
PLEASE - do your own DD and look at PSTI's 'leadership' & experience to do what needs to be done. SO Weak! - and backed up by a BOD that is even weaker! - 0, I repeat, 0 - Biopharma Deal-making experience, anywhere.
http://www.pluristem.com/the-company/
Pretty scary, but explains everything here.
Auto1
Yaky's recent interview with Cade Hildreth confirms nothing happening near or mid-term, 2018-2020 for maybe? a BLA application.
"Since my background is in business and finance, I specialize in assessing global trends, including macro-trends of aging and longevity"... -Yaky
It would be SO much nicer if Yaky 'specialized' in running a biotech company with experience in JV, Deal Making & Commercialization. - but that is alot to ask.
Probably why he is more interested in VR and video games.
"Now, we have moved into large animal studies, with a mutual target to launch a pivotal study in 2017." - Interesting as the article was published in March 2017 - Yaki, so if you knew that then, what's the hold-up?
"This pivotal study is intended also to launch in 2017. We are preparing the company towards filing a BLA, hopefully at the end of 2017 or the beginning of 2018 for this product. Also, we are actively preparing the company to market this product, which is very interesting."
Really? - How do you file a BLA "at the end of 2017" when you don't even know the optimal dose & without a completed pivitol trial? OH...and you are preparing for 'marketing'- this one is hillarious... Um, maybe you should have a 'marketing' department and a sales force to 'prepare' first, eh? (again, this was back in Feb-Mar 2017)
These are the reasons that NOBODY on the street takes these clowns seriously. They are SO far out of their league it's embarrassing.
Ever get the feeling United Therapeutics knew EXACTLY what they were doing when they ended their agreement?!?! Look what their stock has done since severing ties. So disappointing.
Allo, any meaningful comments beyond giddy-up?
https://www.bioinformant.com/yaky-yanay-pluristem-therapeutics/
Auto1
This Is What PLX-Cells Do.. To Rejuvenate Muscles.
https://www.stemcellsportal.com/news/one-gene-closer-regenerative-therapy-muscular-disorders
Amazing Allo! - I wonder why they didn't even mention PSTI or PLX-Cells in the article? Aw, that doesn't matter, just like your anti-aging post/claims (they didnt mention them there either)
You have NO shame.
The Missing Link !
Funny, I like how math often settles out irrational exuberance.
Their investment is now worth a 'whopping' $5M... after 9 years.
Should've bought Amazon, hardly a windfall in this business.
LOL, 13G Dated 11/05/2008
- Exactly, midastouch017! Another joke post by aloevera.
She is paid per post, so it doesn't matter if they are pointless, no-news. She must hane no oversight by her boss, I cannot believe they let a post like this count in her count.
What this really says is - The well is dry, Yaky's recent interview with Cade Hildreth confirms nothing happening near or mid-term, 2018-2020 for maybe? a BLA application.
Dead money, and like dilution.
Cash and Marketable Securities:$33.1 million....
(as of March 31,2017)
Income Statement
Quarterly Revenue as of 3/31/2017
Net Income Applicable To Common Shares -7.8M and increasing...
Dillution by 12/17!
You do the math...tick tock
Cash and Marketable Securities:$33.1 million....
(as of March 31,2017)
2015-2016 Income Statement = -$23M loss/year (before 2017/2018 trial expenses)
You do the math...tick tock
Buy it now $1.40/share!
Someone Bought 400,000 Shares...
So who was it, aloe?
Probably the ESOP plan from PSTI. Guess who gets most of the options, Moe & Larry.
Auto1
"The company is confident in its ability to collaborate with strategic Asian partners."
Did someone move JAPAN out of ASIA when we wern't looking?
PSTI has a crisis of Leadership - these 'co-ceo's' are the reason deals are not getting done. Look NO further or deeper - PERIOD.
We can ALL agree with the facts: Yaky & Zami have NO experience doing what they are doing at this level. Way out of their league, while they pad their options.
-Auto1
Prove me wrong on the direct applicable experience, aloe. 5 mins of DD will make you VERY uncomfortable with these 2 at this level!
This is a potential medicine changer being led from the 'island of mis-fit toys'
"Pluristem does not expect the necessary clarifications regarding the agreement with Innovative Medical to be provided by the end of H1/2017."
Good spin, aloe. Tick, tock - Burn Rate > Resources = dillution or buy-out
Asian Markets Show Heightened Interest in Regenerative Medicine
During the last few months we have seen an increased interest from Asia.
This was particularly evident in China, where the Chinese Food and Drug Administration (CFDA)updated their regulations in order to accelerate the medical regulatory approval process
for regenerative medicine companies. The recent notice states that the CFDA would grant fast-track status to innovative products that address unmet medical needs in the country.
Following the Chinese monetary Policy, Pluristem does not expect the necessary clarifications regarding the agreement with Innovative Medical to be provided by the end of H1/2017. Company will update upon developments, if any.
Pluristem believes that PLX cell therapy products have the ability to play an important role in addressing the needs of Asia’s rapidly growing healthcare markets and aging
population. The company is confident in its ability to collaborate with strategic Asian partners.
Countries Need To Begin Stock-Piling PLX-R18 ASAP !!!
Ummm. Couple of things need to happen before that can happen, but don't let that stop your unbridled enthusiasm, aloe. Fast track, an ACTUAL agreement and funding from NIH for a second, pivitol trial.
In the meantime, I'm glad we have Neupogen.
Short on news, mass hysteria works for your posts.
What's the latest with the good ole NIH/FDA with R18? One would thing that this 'lightening in a bottle' that Yaky keeps in his pocket, would get a fast-track, orphan or maybe a funded pivitol trial by now.
Tick, tock
Burn Rate > Resources = Dillution
Good Point ! He May Have Had To Restock ?
Aloe you make no sense...
Explain the math on that...
PSTI is a no brainer HYPE and DUMP stock!
Follow the PSTI show to see how it turns out.
Make a buck and dont get stuck because of the PSTI HYPE
dont you think corwin..
Hype and Dump?
Yes, we are making a killing shorting this sucker. These $.04 swings are padding my retirement!
Thanks For Sharing Your Nattering Nabob Of Negativity!
My pleasure, allo. Someone has to balance your blatent bumbling babbling bravado of bubbulicious BS.
Please list my 'wrongs' below:
Auto1
Nope ! For Years It's Always Been In December And Sometimes In January !
It has beebn my experience that 'special' grants are awarded ahead or after 'bad news' - not good news, as a retention incentive.
So, allo, are you suggesting that this is a 'special' grant in addition to the annual? OR have they jsut changed the timing?
Nope ! For Years It's Always Been In December And Sometimes In January !
Look At Edgar ! See The 4's In December !
A Sign Of Good Things To Come !
Why is this a sign? They are given out annually, same time every year.
Perhaps
Sounds like the 'staff changes' they need to make were with Zami and Yaky! Still the case - in WAY over their heads, way above their pay grade.
"I'm sure Allo has more specifics but I seem to remember(and they openly admitted) that they had to make some staff changes to bring on someone more experienced and knowledgeable of the clinical trial process with the FDA. Also, as you know, it can take 8-10 years from pre-clinical to approval. Assuming current milestones for approval on CLI and hip replacement are accurate, I don't think they are that far off the mark.
The burning question I have lately is "why did they abandon the PAH path after United Therapeutics pulled out?" It's still listed on their website as part of their pipeline but it doesn't feel like they are doing anything with it currently."
Pluristem on Track to Proceed to a
Things that make you go...Hmmmm
PLX STUDIES....
Thanks for that, allo.
When do you anticipate the first 'read-out' in the R18 HCT IR trial given it is open-label?
Do you think the FDA/BARDA could be waiting on this first glimpse before pulling the trigger? It would see Fukashima data would help, but certainly not <48hr post event dosing, right?
Thx
Auto1
Do you think
the advertizers will continue to support this board of there continues to be only ~7* posters here in a 48 hour period? (*data assumes 1 ID per poster
Allo,
Can you explain the 'thawing' process for PLX cells?
What is the maximum # of R18 cells that can be thawed in a 24hr period using 1 thaw device?
Who manufactures the 'thawing device'?
Thank you.
Auto1